. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: Transpl Infect Dis. 2019 Jul 31;21(5):e13145. doi: 10.1111/tid.13145

Table 4:

Summary of published data for solid organ and hematopoietic cell transplant patients with PTLD

Study Author/year of publication	Patients (n) Total (SOT/alloHCT)	Salient Features of EBV^neg PTLD
Nelson 2000²³	17 (15/2)	- Advanced age compared to EBV^pos PTLD (50y vs 40y) - Later PTLD onset compared to EBV^pos PTLD (50 mo vs 10 mo) - Increased incidence in recent years - More often monomorphic PTLC - More aggressive course - Similar response to reducing immunosuppression
Reshef 2008 ²⁴	30 (30/0)	- Similar age compared to EBV^pos PTLD - Late onset - More often monomorphic PTLD and DLBCL - Associated with failure of grafted organ - Similar response to reducing immunosuppression and Rituximab - Improved survival in renal transplant compared to lung transplant recipients
Luskin 2015²²	176 (176/0)	- Higher recent incidence of EBV^neg PTLD - Late onset - More often monomorphic PTLD - Similar high risk features compared to EBV^pos PTLD - Similar response to reducing immunosuppression and Rituximab - Similar overall survival compared to EBV^pos PTLD
Leblond 1998⁵	11(0/11)	- Later onset compared to EBV^pos PTLD - More often monomorphic PTLD and DLBCL - Inferior survival compared to 21 matched patients without PTLD
Dotti 2000²¹	8 (8/0)	- Later onset compared to EBV^pos PTLD